BFRG

Bullfrog AI Holdings, Inc.

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

The artificial intelligence boom is entering a new phase, one defined less by infrastructure and more by real-world application. Nowhere is that shift more visible than in biotech, where data, diagnostics, and drug discovery are converging into a high-stakes innovation race. Recent developments across public markets show both the promise and the volatility of this transition, as capital flows toward platforms capable of turning complex biological data into actionable outcomes. $KBLB, $BFRG, $RZLV, $ELAB, $EEIQ, $ITRM

Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of artificial intelligence value creation may emerge: healthcare. In a series of trades during late March, Wood aggressively reduced exposure to mega-cap technology and semiconductor names while building a high-conviction position in Tempus AI (NASDAQ:TEM). The move reflects a broader thesis she has increasingly emphasized: the most underestimated frontier for AI innovation is healthcare. As AI infrastructure becomes crowded and capital-intensive, ARK is rotating toward companies applying AI to real-world, high-stakes problems like disease detection, drug development, and clinical decision-making. $ROKU, $NVDA, $TSM, $TSLA, $BFRG, $TGNT

Bullfrog AI announced an agreement with a major global pharmaceutical company to accelerate its drug discovery and clinical development programs.